Md. Abdur Rahim¹, Ahmed Lutful Moben², Rokshana Begum³, Sheikh Mohammad Noor E Alam⁴, Mohammad Ekramul Haque⁵, Sakirul Khan⁶, Musarrat Mahtab⁷, Sheikh Mohammad Fazle Akbar⁸ and Mamun Al Mahtab⁹*

¹Department of Hepatology, International Medical College, Gazipur, Bangladesh
²Department of Hepatology, Kurmitola General Hospital, Dhaka, Bangladesh
³Department of Hepatology, Shaheed Suhrawardy Medical College, Dhaka, Bangladesh
⁴Department of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh
⁵Department of Anaesthesiology, National Institute of Burn & Plastic Surgery, Dhaka, Bangladesh
⁶Research Center for Global and Local Infectious Diseases, Oita University, Yufu, Oita, Japan; Department of Microbiology, Faculty of Medicine, Oita University, Yufu, Oita, Japan; Clinical Research Organization Ltd., Dhaka, Bangladesh
⁷Clinical Research Organization Ltd., Dhaka, Bangladesh
⁸Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine, Ehime, Japan; Research Center for Global and Local Infectious Diseases, Oita University, Yufu, Oita, Japan; Clinical Research Organization Ltd., Dhaka, Bangladesh; Miyakawa Memorial Research Foundation, Tokyo, Japan
⁹Department of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh

*Corresponding Author: Mamun Al Mahtab, Professor, Department of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh.

Received: May 05, 2026; Published: May 31, 2026

Hepatocellular carcinoma (HCC) is primary malignancy of the liver and is one of the most common malignancies in the world. This is more so in the Asia-Pacific region. A significant challenge for HCC management in our part of the globe remains the complex reality that most HCC patients in our country and our region present very late with advanced disease, when we have very little to offer to them. As such, in addition to standard therapeutic approaches, innovative strategies are warranted to address the challenges of managing patients with advanced HCC. Over the past several years, our group has explored various methods, ranging from food supplements and traditional medicine to combination therapy, for the management of end-stage HCC. The purpose of this article is to review the works carried out by our group so far involving advanced HCC patients with or without metastasis, of variable etiology and severity of underline liver disease, without any second malignancy to summarize the knowledge and experience that we have so far gathered and outline our way forward.

References

1. Ferlay J., et al. “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012”. International Journal of Cancer5 (2015): E359-386.
2. Forman D., et al. “Cancer Incidence in Five Continents”. Vol. X. IARC Scientific Publications No. 164. International Agency for Research on Cancer Lyon, France (2014): 70-75.
3. Hussain SA and Sullivan R. “Cancer control in Bangladesh”. Japanese Journal of Clinical Oncology12 (2013): 1159-1169.
4. Noor-E-Alam SM. “Management of Hepatocellular Carcinoma: Bangladesh Perspective”. Euroasian Journal of Hepatogastroenterology1 (2018): 52-53.
5. Ashrafujjaman M., et al. “Role of Biobran (Arabinoxylan Rice Bran) on Patients with Advanced Stage Hepatocellular Carcinoma”. Euroasian Journal of Hepatogastroenterology2 (2023): 84-88.
6. Matsui Y., et al. “Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study”. Journal of Hepatology1 (2002): 78-86.
7. Vilar Gomez E., et al. “Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial”. BMJ Open2 (2011): e000140.
8. Morihara D., et al. “Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma”. Hepatology Research7 (2012): 658-667.
9. Nishikawa H., et al. “Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma”. World Journal of Gastroenterology12 (2012): 1379-1384.
10. Murugan RS., et al. “Black tea polyphenols target matrix metalloproteinases, RECK, proangiogenic molecules and histone deacetylase in a rat hepatocarcinogenesis model”. Anticancer Research6 (2009): 2301-2305.
11. Al-Mahtab M., et al. “Increased survival of patients with end-stage hepatocellular carcinoma due to intake of ONCOXIN®, a dietary supplement”. Indian Journal of Cancer3 (2015): 443-446.
12. Mahtab MAI., et al. “Effect of Oncoxin, a Food Supplement, on Terminal-stage Hepatocellular Carcinoma Patients”. Bengal Physician Journal3 (2021): 63-66.
13. Kumar M and Panda D. “Role of supportive care for terminal stage hepatocellular carcinoma”. Journal of Clinical and Experimental Hepatology 4 (2014): S130-139.
14. Rahman MR. “Effect of Phyllanthus emblica in Terminal Stage Hepatocellular Carcinoma patients”. Thesis submitted to Bangladesh Medical University for partial fulfillment of Doctor of Medicine in Hepatology (2025).
15. Mahtab Rahim MA., et al. “Survey of Nivolumab and Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma”. Asian Journal of Research and Reports in Hepatology1 (2023): 72-77.
16. Yau T., et al. “Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial”. Lancet Oncology1 (2022): 77-90.
17. Mahtab MA., et al. “Real Life Experience of Combining Atezolizumab (Immunotherapy) and Bevacizumab (Antiangiogenic Agent) in Patients with Unresectable Hepatocellular Carcinoma in Bangladesh". Acta Scientific Medical Sciences6 (2022): 227-230.
18. Al Mahtab M., et al. “Treatment by Transarterial Chemoembolization and Sorafenib for Hepatocellular Carcinoma vs Advanced Hepatocellular Carcinoma in Bangladesh: A Real-life Situation”. Euroasian Journal of Hepatogastroenterology2 (2019): 63-66.
19. Finn RS., et al. “Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial”. Journal of Clinical Oncology3 (2020): 193-202.
20. Yau T., et al. “Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial”. Lancet Oncology1 (2022): 77-90.
21. Finn RS., et al. “Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma”. The New England Journal of Medicine20 (2020): 1894-1905.
22. Hamid MA., et al. “Human cancer germline antigen-specific cytotoxic T cell-what can we learn from patient”. Cell Molecular Immunology7 (2020): 684-692.
23. Hart DN. “Dendritic cells: unique leukocyte populations which control the primary immune response”. Blood 9 (1997): 3245-3287.
24. Banchereau J and Steinman RM. “Dendritic cells and the control of immunity”. Nature 6673 (1998): 245-252.
25. Hermans IF., et al. “Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors”. Cancer Research17 (1998): 3909-3917.
26. Akbar SM., et al. “Vaccine therapy for hepatitis B virus carrier”. Current Drug Targets - Infectious Disorders2 (2004): 93-101.
27. Steinman RM and Pope M. “Exploiting dendritic cells to improve vaccine efficacy”. Journal of Clinical Investigation12 (2002): 1519-1526.
28. Mellman I and Steinman RM. “Dendritic cells: specialized and regulated antigen processing machines”. Cell 3 (2001): 255-258.
29. Gong J., et al. “Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells”. Nature Medicine 3 (5 (1997): 558-561.
30. Ninomiya T., et al. “Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma”. Journal of Hepatology2 (1999): 323-31.
31. Gabrilovich DI., et al. “Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts”. Cell Immunology1 (1996): 101-110.
32. Okada H., et al. “Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms”. International Journal of Cancer2 (1998): 196-201.
33. Hsu FJ., et al. “Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells”. Nature Medicine1 (1996): 52-58.
34. Mocellin S., et al. “Part I: Vaccines for solid tumours”. Lancet Oncology11 (2004): 681-689.
35. Onji M. “Dendritic cells in clinics”. Springer, Tokyo (2004).
36. Akbar SM., et al. “Dendritic cell-based therapies in the bench and the bedsides”. Current Drug Targets - Inflammation & Allergy 3 (2004): 305-310.
37. Fazle Akbar SM., et al. “Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells”. Journal of Hepatology1 (2007): 60-66.
38. Kumagi T., et al. “Increased survival and decreased tumor size due to intratumoral injection of ethanol followed by administration of immature dendritic cells”. International Journal of Oncology4 (2003): 949-955.
39. Kumagi T., et al. “Administration of dendritic cells in cancer nodules in hepatocellular carcinoma”. Oncology Report4 (2005): 969-973.
40. Labeur MS., et al. “Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage”. Journal of Immunology1 (1999): 168-175.
41. Steinbrink K., et al. “Induction of tolerance by IL-10-treated dendritic cells”. Journal of Immunology10 (1997): 4772-4780.
42. Enk AH., et al. “Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma”. International Journal of Cancer3 (1997): 309-316.
43. Fields RC., et al. “Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo”. Proceedings of the National Academy of Sciences of the United States of America16 (1998): 9482-9487.
44. Gong J., et al. “Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells”. Proceedings of the National Academy of Sciences of the United States of America11 (1998): 6279-6283.
45. Chen B., et al. “The role of tumor necrosis factor alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro”. Blood 12 (1998): 4652-4661.
46. Zitvogel L., et al. “Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes”. Nature Medicine5 (1998): 594-600.
47. Harada M., et al. “Role of the endogenous production of interleukin 12 in immunotherapy”. Cancer Research14 (1998): 3073-3077.
48. Robert C. “A decade of immune-checkpoint inhibitors in cancer therapy”. Nature Communication1 (2020): 3801.
49. Chen H., et al. “The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances”. MedComm10 (2025): e70412.

Citation

Citation: Mamun Al Mahtab., et al. “Homegrown Solutions for Advanced Hepatocellular Carcinoma in Bangladesh". Acta Scientific Medical Sciences 10.6 (2026): 82-88.

Copyright

Copyright: © 2026 Mamun Al Mahtab., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.